What the company does
Hyundai Pharmaceutical makes prescription drugs, over-the-counter medicines, functional foods, and cosmetics, ranging from treatments for dementia and abnormal cholesterol levels to a well-known hair-loss remedy and a dietary-fibre drink.
It supplies hospitals, clinics, pharmacies, and wholesalers across South Korea, and is listed on KOSPI, Korea's main stock exchange. Its business spans four distinct segments, pharmaceuticals, food, cosmetics, and medical devices, with the food segment anchored by a single long-running dietary-fibre beverage brand.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$131M
- FY2024US$127.3M
- FY2025US$139M
Operating profit
- FY2023US$5M
- FY2024US$131.1K
- FY2025US$3M
Net income
- FY2023US$4.4M
- FY2024−US$416.6K
- FY2025US$1.8M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The company entered the cosmetics business using in-house peptide and compound-ingredient technology developed through its own pharmaceutical research capabilities.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?